Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Dejager

Showing results (41-50 of 49) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 49 results.
Diabetes, Obesity & Metabolism|February 16, 2007
Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetesJ Rosenstock, S W Kim, M A Baron, et al.
Diabetes, Obesity & Metabolism|July 24, 2010
Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year studyD R Matthews, S Dejager, B Ahren, et al.
Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Metabolisme|August 30, 2008
Efficacy and safety of vildagliptin monotherapy during 2-year treatment of drug-naïve patients with type 2 diabetes: comparison with metforminB Göke, K Hershon, D Kerr, et al.
Diabetes & Metabolism|October 16, 2010
How patients' attitudes and opinions influence self-care behaviours in type 2 diabetes. Insights from the French DIABASIS SurveyH Mosnier-Pudar, G Hochberg, E Eschwege, et al.
Diabetes & Metabolism|July 20, 2012
Continuous glucose profiles with vildagliptin versus sitagliptin in add-on to metformin: results from the randomized Optima studyB Guerci, L Monnier, P Serusclat, et al.
The Journal of Clinical Endocrinology and Metabolism|August 6, 2002
A comprehensive endocrine description of Kennedy's disease revealing androgen insensitivity linked to CAG repeat lengthS Dejager, H Bry-Gauillard, E Bruckert, et al.
Diabetes, Obesity & Metabolism|December 21, 2007
Robust improvements in fasting and prandial measures of beta-cell function with vildagliptin in drug-naïve patients: analysis of pooled vildagliptin monotherapy databaseR E Pratley, A Schweizer, J Rosenstock, et al.
Diabetes & Metabolism|March 24, 2009
How do patients with type 2 diabetes perceive their disease? Insights from the French DIABASIS surveyH Mosnier-Pudar, G Hochberg, E Eschwege, et al.
The Journal of Clinical Endocrinology and Metabolism|November 25, 2004
Octreotide (long-acting release formulation) treatment in patients with graves' orbitopathy: clinical results of a four-month, randomized, placebo-controlled, double-blind studyJ L Wémeau, P Caron, A Beckers, et al.
Pageof 5

Showing results (41-50 of 49) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 49 results.
Diabetes, Obesity & Metabolism|February 16, 2007
Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetesJ Rosenstock, S W Kim, M A Baron, et al.
Diabetes, Obesity & Metabolism|July 24, 2010
Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year studyD R Matthews, S Dejager, B Ahren, et al.
Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Metabolisme|August 30, 2008
Efficacy and safety of vildagliptin monotherapy during 2-year treatment of drug-naïve patients with type 2 diabetes: comparison with metforminB Göke, K Hershon, D Kerr, et al.
Diabetes & Metabolism|October 16, 2010
How patients' attitudes and opinions influence self-care behaviours in type 2 diabetes. Insights from the French DIABASIS SurveyH Mosnier-Pudar, G Hochberg, E Eschwege, et al.
Diabetes & Metabolism|July 20, 2012
Continuous glucose profiles with vildagliptin versus sitagliptin in add-on to metformin: results from the randomized Optima studyB Guerci, L Monnier, P Serusclat, et al.
The Journal of Clinical Endocrinology and Metabolism|August 6, 2002
A comprehensive endocrine description of Kennedy's disease revealing androgen insensitivity linked to CAG repeat lengthS Dejager, H Bry-Gauillard, E Bruckert, et al.
Diabetes, Obesity & Metabolism|December 21, 2007
Robust improvements in fasting and prandial measures of beta-cell function with vildagliptin in drug-naïve patients: analysis of pooled vildagliptin monotherapy databaseR E Pratley, A Schweizer, J Rosenstock, et al.
Diabetes & Metabolism|March 24, 2009
How do patients with type 2 diabetes perceive their disease? Insights from the French DIABASIS surveyH Mosnier-Pudar, G Hochberg, E Eschwege, et al.
The Journal of Clinical Endocrinology and Metabolism|November 25, 2004
Octreotide (long-acting release formulation) treatment in patients with graves' orbitopathy: clinical results of a four-month, randomized, placebo-controlled, double-blind studyJ L Wémeau, P Caron, A Beckers, et al.
Pageof 5